Acorda's $525M Civitas buy opens Parkinson's pipeline

September 24, 2014 7:25 PM

3 0

Acorda's $525M Civitas buy opens Parkinson's pipeline

Acorda Therapeutics is plunking down $525 million in cash to buy the Ardsley, NY, biotech Civitas. The deal means Acorda's pipeline of experimental stroke, epilepsy, spinal cord injury and neuropathic pain therapies will now include experimental Parkinson's disease treatment CVT-301, which just wrapped Phase-IIb clinical trial testing. The deal also gives Acorda rights to Civitas's ARCUS technology, which supports the inhaler that goes along with the CVT-301 powder.

Civitas's treatment focuses on what are called the “OFF” episodes Parkinson's disease patients experience, which are when blood concentrations of treatments, such as levodopa, fluctuate and can cause symptoms such as tremor, stiffness and immobility to return. Acorda President and CEO Ron Cohen desc...

Also read: Russia's FG Budushchee rises in market debut

Read more

To category page